OCUGEN INC. - COMMON STOCK

Ocugen to Present at May 2024 Investor Conferences

10 May 2024 06:45:07 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

03 May 2024 06:30:05 By Nasdaq GlobeNewswire

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

02 May 2024 06:15:46 By Nasdaq GlobeNewswire

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

29 Apr 2024 05:45:00 By Nasdaq GlobeNewswire

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 Apr 2024 08:05:24 By Nasdaq GlobeNewswire

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

26 Apr 2024 05:30:40 By Nasdaq GlobeNewswire

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

19 Apr 2024 06:13:05 By Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

12 Apr 2024 06:30:34 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

10 Apr 2024 06:02:26 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

08 Apr 2024 05:30:43 By Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

05 Apr 2024 06:02:21 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

02 Apr 2024 07:00:39 By Nasdaq GlobeNewswire

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

01 Apr 2024 17:08:46 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023

01 Apr 2024 16:43:45 By Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

18 Mar 2024 05:30:50 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

13 Mar 2024 07:00:54 By Nasdaq GlobeNewswire

Ocugen to Present at Investing in Cures Summit

06 Mar 2024 06:30:09 By Nasdaq GlobeNewswire

Ocugen Clinical Showcase Webcast Now Available

28 Feb 2024 07:00:26 By Nasdaq GlobeNewswire

Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit

26 Feb 2024 07:30:13 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire